Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Missed Intuitive Surgical? Buy This Stock Instead
02:15pm, Wednesday, 20'th Apr 2022 The Motley Fool
Much as Intuitive Surgical redefined the surgical field, this company is updating how abnormal heart rhythms are diagnosed.
Johnson & Johnson: Q1 Earnings Offer Another Reason Why Stock Is A Long-Term Buy
09:52am, Wednesday, 20'th Apr 2022 Investing.comBristol Myers Squibb - AbbVie 2.0?
09:15am, Wednesday, 20'th Apr 2022
BMY has rallied since late November 2021, from $53 to $77 currently, and one can question whether the shares still represent good value or may already be overvalued. The company's current portfolio ge
Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?
03:50pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?
10:20am, Tuesday, 19'th Apr 2022 Zacks Investment Research
Smart Beta ETF report for FLQL
Exelixis (EXEL) Initiates Early Stage Study of Lymphoma
04:45pm, Monday, 18'th Apr 2022 Zacks Investment Research
Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.
Why Nektar Therapeutics Stock Is Crashing Today
03:30pm, Monday, 18'th Apr 2022 The Motley Fool
The company is throwing in the towel on its lead pipeline program.
Inflation is raging, but these 16 companies have pricing power
03:10pm, Monday, 18'th Apr 2022 MarketWatch
High inflation threatens to end a decade of improving profitability for U.S. companies, but these companies are bucking the trend.
Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures
01:32pm, Monday, 18'th Apr 2022 Zacks Investment Research
Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development prog
Nektar, Bristol Myers Squibb end clinical development of combination therapy including Opdivo
10:39am, Monday, 18'th Apr 2022
Shares of Nektar Therapeutics Inc. NKTR, -34.98% were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Mye
Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program
09:01am, Monday, 18'th Apr 2022
Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb Co (NYSE: BMY) have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
10:20am, Friday, 15'th Apr 2022 Zacks Investment Research
Sector ETF report for XPH
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
09:45pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Bristol Myers Squibb (BMY) closed at $77.51 in the latest trading session, marking a +0.83% move from the prior day.
2 Unstoppable Green Flags for AbbVie
11:00am, Thursday, 14'th Apr 2022 The Motley Fool
There's a silver lining around an approaching dark cloud.
Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC
06:57pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.
